We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. As per the research study, this region is expected to register a progressive growth rate in the near future. Other players include Biogen Idec, Inc. The blood disorders segment is projected to grow at a lucrative rate during the forecast period.
Furthermore, rising geriatric population in countries such as Japan and India is projected to provide a lucrative opportunity for the growth of the market. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles.
Similarly, price regulation in Japan and reduced health budget in India, have raised cost containment demands. Furthermore, rising geriatric population in countries such as Japan and India is projected to provide a lucrative opportunity for the growth of the market.
Most of the lucrative products in biosimilars industries are monoclonal antibodies, G-CSF erythropoietin and peptide. Biosimilar drugs are highly identical to approved biologic drugs.
High prevalence of chronic diseases such as diabetes, cancer, growth hormone deficiency, and anemia is expected to further fuel market expansion in near future. In the coming decade, there would be a rise in the patent expiration of several existing biological drugs, such as Erbitux, Avastin, Orencia, and others, which would provide an opportunity for many innovator companies as well as generic manufacturers to offer services, specially tailored toward biosimilars.
The companies such as Sandoz, Merck Serono, and Celltrion are continuously seeking approvals across different geographies. Competitive Landscape The global biosimilars market is consolidated in nature with the majority of the share held by a few well-established players.
The research study has offered a complete overview of the competitive scenario of the global biosimilars market.
Furthermore, the growth of the biosimilars market is hampered due to the lack of regulatory guidelines, consumers brand preferences, reluctance of physicians to prescribed biosimilars and the high capital required for research and development.
As stated by Canadian Diabetes Association, prevalence of diabetes is growing in Canada and it is projected to reach around 5.
A biosimilar takes around seven to eight years for its development, with high financial investments ranging between USD million and USD million, which are considerably much higher than the USD 1 million to USD 5 million for generic production.
They possess similar medical properties in terms of potency, safety, and efficacy to original biologic products. These companies are subsidiaries of global companies such as Merck and Novartis, which enable them to invest into the biosimilar studies.
Recombinant glycosylated proteins are expected to hold the largest share of the market during the forecast period. Governments of several countries are emphasizing on cost effective drug synthesis.
As per the research study, this region is expected to register a progressive growth rate in the near future. In addition, the growing prevalence of different ailments across the globe is predicted to fuel the growth of the market.
The study provides historical data from, and along with a forecast from to based on revenue USD Million. The global biosimilars market has been segmented as: The manufacturers are concentrating on getting approvals in various regions to increase their presence globally.
This brings into the light the need for developing new, improved, efficient, and affordable therapeutics. Patent expiration is a key factor that largely influences the biosimilars market.
In addition, the strict regulatory framework and the rising products in the pipeline are estimated to contribute substantially towards the development of the Europe biosimilars market in the next few years. The global biosimilars market size was valued at USD billion in It is anticipated to exhibit a CAGR of % during the forecast period.
Cost-effectiveness of biosimilar drugs and high prevalence of chronic disorders globally are some major factors contributing to market growth. 6 Biosimilars Market, By Type of Product.
The post Biosimilar Market Global Industry Analysis, Size, Share, Growth by appeared. Biosimilars Market - Global Biosimilars Industry Size, Share, Growth, Analysis, Research And Forecast Report, To Global biosimilars market size was valued at billion in and is expected to grow on account of increasing prevalence of chronic diseases such as cancer and autoimmune disorders.
Europe accounted for the largest share of the global biosimilars market in Europe accounted for largest share of the global biosimilars market infollowed by Asia. Growth in this regional market is expected to be driven by patent expiry of biologic products & the launch of new biosimilars, rising incidence of chronic disorders, and.
The global biosimilar market has been segmented by product class and geography. By geography, it has been segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America. North America accounted for the largest share, accounting for. The Global biosimilars products market is segmented into Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Interferon, G-CSF, peptide and other biosimilars.
Patent expiration is a key factor that largely influences the biosimilars market.Global biosimilars market size share global